Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT J BUYNAK

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1508977984
CMS profile
340544
Location
VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,804.68

27 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,807.28 10
Food and Beverage $997.40 17

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $1,924.95 17
AstraZeneca Pharmaceuticals LP $729.73 8
Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 2

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT J BUYNAK

NPI 1508977984 · CMS profile ID 340544

Allopathic & Osteopathic Physicians / Internal Medicine

VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

27 matching records · $2,804.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 27 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–27 of 27.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ModernaTX, Inc. $240.0009/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558606 CMS
ModernaTX, Inc. $318.9609/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558608 CMS
ModernaTX, Inc. $177.0109/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558610 CMS
ModernaTX, Inc. $265.5309/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558612 CMS
ModernaTX, Inc. $120.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558614 CMS
ModernaTX, Inc. $45.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558616 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558618 CMS
ModernaTX, Inc. $81.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558620 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558622 CMS
AstraZeneca Pharmaceuticals LP $24.4409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104288350 CMS
AstraZeneca Pharmaceuticals LP $27.9409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104385089 CMS
AstraZeneca Pharmaceuticals LP $27.9409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104473474 CMS
AstraZeneca Pharmaceuticals LP $81.0009/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104543482 CMS
AstraZeneca Pharmaceuticals LP $97.7809/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105367592 CMS
AstraZeneca Pharmaceuticals LP $71.2409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105375956 CMS
AstraZeneca Pharmaceuticals LP $292.3309/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105442631 CMS
AstraZeneca Pharmaceuticals LP $107.0609/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105540731 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $35.0001/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118039628 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $115.0001/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118039630 CMS
ModernaTX, Inc. $150.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558536 CMS
ModernaTX, Inc. $217.3501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558538 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558540 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558542 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558544 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558600 CMS
ModernaTX, Inc. $50.0501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558602 CMS
ModernaTX, Inc. $50.0501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558604 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,627.38 35
PY2022 $1,515.77 9
PY2023 $2,547.31 21
PY2024 $2,804.68 27
PY2025 $2,542.53 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,038,550.53 603
PY2024 Principal investigator $5,031,915.33 601
PY2023 Recipient $906.71 2
PY2023 Principal investigator $4,138,599.32 2,384
PY2022 Recipient $3,104.59 10
PY2022 Principal investigator $5,204,363.35 1,133
PY2021 Principal investigator $3,348,948.64 610
PY2020 Recipient $1,489.26 13
PY2020 Principal investigator $1,938,354.41 292
PY2019 Recipient $658.79 10
PY2019 Principal investigator $1,439,149.33 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

603 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $136.60 12/29/2025 Non-covered Recipient Entity
Velocity Clinical Research - Valparaiso
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971017
Principal investigator 1 Currax Pharmaceuticals LLC $6,056.43 12/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718380
Principal investigator 1 ModernaTX, Inc. $149.67 12/23/2025 Non-covered Recipient Entity
Velocity Clinical Research - Valparaiso
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971019
Principal investigator 1 Novavax Inc $14,500.00 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Healthy Participants greater than or equal to 50 years of age, to less than or equal to 80 Years of Age No dispute reported 06/30/2026 1242918947
Principal investigator 1 Novavax Inc $2,000.00 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Healthy Participants greater than or equal to 50 years of age, to less than or equal to 80 Years of Age No dispute reported 06/30/2026 1242919726
Principal investigator 1 Novavax Inc $3,269.00 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Healthy Participants greater than or equal to 50 years of age, to less than or equal to 80 Years of Age No dispute reported 06/30/2026 1242921067
Principal investigator 1 Novavax Inc $1,500.00 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Healthy Participants greater than or equal to 50 years of age, to less than or equal to 80 Years of Age No dispute reported 06/30/2026 1242921414
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272136
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272138
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272140
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272142
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272144
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272147
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272150
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272152
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272154
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272156
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272158
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272160
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272162
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272164
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272166
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272168
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272170
Principal investigator 1 Seqirus USA Inc $1,089.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272422
Principal investigator 1 Seqirus USA Inc $1,089.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272424
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272430
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272432
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272434
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272436
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272438
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272440
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272442
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272444
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272446
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272448
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272450
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272452
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272454
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272456
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272458
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272460
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272462
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272464
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272466
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272468
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272470
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272474
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272476
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272478
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272480
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272482
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272484
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272486
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272488
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272490
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272492
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272494
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272496
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272498
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272501
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272504
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272506
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272508
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272510
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272512
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272514
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272516
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272518
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272520
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272522
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272524
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272526
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272528
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272530
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272532
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272534
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272536
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272538
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272540
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272542
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272544
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273212
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273214
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273218
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279655
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279657
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279659
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279661
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279663
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279665
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279667
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280315
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280317
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280319
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280321
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280641
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280643
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280701
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280703
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280705
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280707
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280709
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283411
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283413
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283415
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283417
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283421
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283423
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283425
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283427
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283429
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283431
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274148
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274150
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274152
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274154
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274156
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274159
Principal investigator 1 Seqirus USA Inc $1,019.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274288
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274482
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274484
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274486
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274488
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274490
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274562
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274564
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275194
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275196
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275198
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275200
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275396
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275398
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275400
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275402
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275404
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275407
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275410
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275412
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275414
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275416
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275418
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275420
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275422
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275424
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275426
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275428
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275430
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275432
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275434
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275436
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275438
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275440
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275444
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275446
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275448
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275450
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275452
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275454
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275456
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275458
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275460
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275462
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275464
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275466
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275468
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275470
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275472
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275474
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275476
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275478
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275480
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275482
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275484
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275560
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275562
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275564
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275566
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275568
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275570
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275572
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275574
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275576
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275578
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275580
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275582
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275584
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275586
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275588
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275590
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275592
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275594
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275596
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275598
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275612
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275614
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275616
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275618
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275620
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275622
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275624
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275626
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275628
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275630
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275632
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275634
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275636
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275638
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275640
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275642
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275644
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275646
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275648
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275650
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275652
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 12/17/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723018
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 12/17/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723020
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 12/17/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723022
Principal investigator 1 ModernaTX, Inc. $10,000.00 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) No dispute reported 06/30/2026 1252946672
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,887.14 12/17/2025 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190310915
Principal investigator 1 Novavax Inc $6,538.00 12/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Healthy Participants greater than or equal to 50 years of age, to less than or equal to 80 Years of Age No dispute reported 06/30/2026 1242921071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,412.05 12/10/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215518277
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,470.00 12/10/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800832
Principal investigator 1 ModernaTX, Inc. $54.64 12/10/2025 Non-covered Recipient Entity
Velocity Clinical Research - Valparaiso
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $885.15 12/03/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215518271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $100.00 12/03/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215518274
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,533.00 12/03/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800958
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 12/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800954
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,000.00 12/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800956
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722886
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,200.00 12/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800830
Principal investigator 1 ModernaTX, Inc. $4,718.65 12/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ?60 Years of Age No dispute reported 06/30/2026 1252971065
Principal investigator 1 ModernaTX, Inc. $556.70 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971037
Principal investigator 1 ModernaTX, Inc. $8,934.75 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971039
Principal investigator 1 ModernaTX, Inc. $7,733.00 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971113
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 11/26/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800826
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 11/26/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800828
Principal investigator 1 ModernaTX, Inc. $30,000.00 11/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) No dispute reported 06/30/2026 1252946670
Principal investigator 1 ModernaTX, Inc. $136.60 11/20/2025 Non-covered Recipient Entity
Velocity Clinical Research - Valparaiso
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971077
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722894
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 11/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722896
Principal investigator 1 Boehringer Ingelheim International GmbH $12.18 11/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722898
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 11/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722900
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,939.00 11/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800824
Principal investigator 1 Currax Pharmaceuticals LLC $9,506.95 11/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718262
Principal investigator 1 ModernaTX, Inc. $270.00 11/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252971001
Principal investigator 1 ModernaTX, Inc. $94.50 11/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252971125
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,400.00 11/10/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800952
Principal investigator 1 Alnylam Pharmaceuticals Inc. $19,500.00 11/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215518262
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 11/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215518265
Principal investigator 1 ModernaTX, Inc. $843.75 11/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252971041
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723016
Principal investigator 1 Seqirus USA Inc $6,923.88 10/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809996
Principal investigator 1 Seqirus USA Inc $1,902.69 10/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810001
Principal investigator 1 Currax Pharmaceuticals LLC $325.00 10/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718168
Principal investigator 1 ModernaTX, Inc. $199.56 10/29/2025 Non-covered Recipient Entity
Velocity Clinical Research - Valparaiso
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971153
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 10/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722888
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 10/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722890
Principal investigator 1 Boehringer Ingelheim International GmbH $41.40 10/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722892
Principal investigator 1 ModernaTX, Inc. $10,298.95 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971033
Principal investigator 1 ModernaTX, Inc. $7,983.80 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971035
Principal investigator 1 ModernaTX, Inc. $686.85 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971115
Principal investigator 1 ModernaTX, Inc. $34,896.65 10/15/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ?60 Years of Age No dispute reported 06/30/2026 1252971131
Principal investigator 1 Currax Pharmaceuticals LLC $7,006.72 10/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718048
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,353.40 10/10/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800948
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34,871.00 10/03/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800078
Principal investigator 1 Alnylam Pharmaceuticals Inc. $144.00 10/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518245
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723014
Principal investigator 1 ModernaTX, Inc. $9,000.00 10/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ?60 Years of Age No dispute reported 06/30/2026 1252971063
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ?60 Years of Age No dispute reported 06/30/2026 1252971093
Principal investigator 1 ModernaTX, Inc. $9,000.00 10/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ?60 Years of Age No dispute reported 06/30/2026 1252971133
Principal investigator 1 ModernaTX, Inc. $11,412.35 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971075
Principal investigator 1 ModernaTX, Inc. $2,866.15 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971099
Principal investigator 1 ModernaTX, Inc. $7,440.40 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971143
Principal investigator 1 Seqirus USA Inc $70.00 09/29/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185276636
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 09/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722882
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722884
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 09/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723010
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723012
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/22/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220807455
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220807465
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220807467
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220807469
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220807471
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220807473
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220807475
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220807477
Principal investigator 1 Seqirus USA Inc $1,893.60 09/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276684
Principal investigator 1 Seqirus USA Inc $111.30 09/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276796
Principal investigator 1 Seqirus USA Inc $110.98 09/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276818
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42,757.20 09/03/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800950
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723002
Principal investigator 1 ModernaTX, Inc. $2,783.50 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971081
Principal investigator 1 ModernaTX, Inc. $8,192.80 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971105
Principal investigator 1 ModernaTX, Inc. $4,963.75 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971121
Principal investigator 1 Seqirus USA Inc $14,500.00 08/28/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276908
Principal investigator 1 Seqirus USA Inc $27,126.40 08/28/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276928
Principal investigator 1 Seqirus USA Inc $2,000.00 08/28/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276980
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 08/26/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722878
Principal investigator 1 Boehringer Ingelheim International GmbH $442.20 08/26/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722880
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,975.00 08/20/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800076
Principal investigator 1 ModernaTX, Inc. $36,837.64 08/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252971043
Principal investigator 1 ModernaTX, Inc. $60.75 08/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252970989
Principal investigator 1 ModernaTX, Inc. $3,226.50 08/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252971045
Principal investigator 1 ModernaTX, Inc. $9,337.95 08/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252971083
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722858
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722860
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722862
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722864
Principal investigator 1 Boehringer Ingelheim International GmbH $61.58 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722994
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723000
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 07/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722874
Principal investigator 1 Boehringer Ingelheim International GmbH $15.66 07/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722876
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 07/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723004
Principal investigator 1 Boehringer Ingelheim International GmbH $19.14 07/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723006
Principal investigator 1 Boehringer Ingelheim International GmbH $4.14 07/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723008
Principal investigator 1 ModernaTX, Inc. $2,173.60 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971071
Principal investigator 1 ModernaTX, Inc. $4,963.75 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971111
Principal investigator 1 Verona Pharma, Inc. $11,500.00 07/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891897
Principal investigator 1 Verona Pharma, Inc. $2,400.00 07/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891899
Principal investigator 1 ModernaTX, Inc. $16,960.00 07/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,200.00 07/16/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $675.00 07/16/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518494
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,368.00 07/09/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800072
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,425.26 07/09/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800074
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722866
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722868
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722870
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722872
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722986
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722988
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722990
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722992
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722996
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722998
Principal investigator 1 ModernaTX, Inc. $5,643.00 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971101
Principal investigator 1 ModernaTX, Inc. $33,753.50 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971141
Principal investigator 1 ModernaTX, Inc. $1,391.75 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971145
Principal investigator 1 Amgen Inc. $69,863.00 06/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246651455
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,159.00 06/26/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800070
Principal investigator 1 ModernaTX, Inc. $124,701.81 06/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252970991
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 06/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722856
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 06/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722984
Principal investigator 1 Currax Pharmaceuticals LLC $11,467.01 06/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717948
Principal investigator 1 Currax Pharmaceuticals LLC $182.00 06/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718028
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,499.00 06/20/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518378
Principal investigator 1 ModernaTX, Inc. $1,262.30 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252971007
Principal investigator 1 ModernaTX, Inc. $7,962.90 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971013
Principal investigator 1 ModernaTX, Inc. $9,742.25 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971021
Principal investigator 1 ModernaTX, Inc. $166.40 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252971057
Principal investigator 1 ModernaTX, Inc. $7,820.80 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252971059
Principal investigator 1 ModernaTX, Inc. $14,246.85 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252971061
Principal investigator 1 ModernaTX, Inc. $686.85 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971073
Principal investigator 1 ModernaTX, Inc. $20,997.50 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252971091
Principal investigator 1 ModernaTX, Inc. $37,724.50 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971137
Principal investigator 1 ModernaTX, Inc. $2,866.15 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971157
Principal investigator 1 Currax Pharmaceuticals LLC $2,203.50 06/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717599
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,473.40 06/12/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800946
Principal investigator 1 ModernaTX, Inc. $36,480.00 06/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005819
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 06/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185543062
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,875.00 06/10/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800942
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,510.26 06/10/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800944
Principal investigator 1 Amgen Inc. $17,995.84 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246651338
Principal investigator 1 ModernaTX, Inc. $80.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005803
Principal investigator 1 ModernaTX, Inc. $29,925.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005809
Principal investigator 1 ModernaTX, Inc. $3,905.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005821
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722836
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722838
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722840
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722842
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722962
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722964
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722966
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722968
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722970
Principal investigator 1 Currax Pharmaceuticals LLC $3,900.00 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717681
Principal investigator 1 Currax Pharmaceuticals LLC $1,300.00 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717791
Principal investigator 1 Currax Pharmaceuticals LLC $10,898.25 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717875
Principal investigator 1 Currax Pharmaceuticals LLC $2,978.30 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717914
Principal investigator 1 ModernaTX, Inc. $21,711.30 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971097
Principal investigator 1 ModernaTX, Inc. $8,067.40 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971135
Principal investigator 1 ModernaTX, Inc. $9,927.50 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971151
Principal investigator 1 ModernaTX, Inc. $281,200.00 05/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005797
Principal investigator 1 ModernaTX, Inc. $3,674.00 05/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005799
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,787.00 05/21/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800068
Principal investigator 1 PFIZER INC. $26,516.69 05/21/2025 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228782599
Principal investigator 1 ModernaTX, Inc. $55.55 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252970997
Principal investigator 1 ModernaTX, Inc. $284.88 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252970999
Principal investigator 1 ModernaTX, Inc. $325.44 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252971003
Principal investigator 1 ModernaTX, Inc. $3,298.56 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252971055
Principal investigator 1 ModernaTX, Inc. $1,859.84 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252971085
Principal investigator 1 ModernaTX, Inc. $83.38 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252971087
Principal investigator 1 ModernaTX, Inc. $1,664.74 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252971129
Principal investigator 1 ModernaTX, Inc. $4,170.60 05/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age No dispute reported 06/30/2026 1252971049
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $170.00 05/12/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220807453
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $170.00 05/12/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220807463
Principal investigator 1 AstraZeneca Pharmaceuticals LP $93,486.66 05/09/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) No dispute reported 06/30/2026 1185543058
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $160.92 05/07/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220807461
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $438.00 05/06/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220807451
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,805.74 05/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800064
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $26,327.00 05/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800066
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $21,914.10 05/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800940
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722826
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722828
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722830
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722832
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722834
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722952
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722954
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722956
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722958
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722960
Principal investigator 1 ModernaTX, Inc. $7,921.10 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971023
Principal investigator 1 ModernaTX, Inc. $2,060.55 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971031
Principal investigator 1 ModernaTX, Inc. $27,278.30 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971095
Principal investigator 1 ModernaTX, Inc. $6,012.00 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005815
Principal investigator 1 Currax Pharmaceuticals LLC $6,193.56 04/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717757
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722844
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722846
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722848
Principal investigator 1 Boehringer Ingelheim International GmbH $530.64 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722850
Principal investigator 1 Boehringer Ingelheim International GmbH $27.84 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722852
Principal investigator 1 Boehringer Ingelheim International GmbH $57.96 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722854
Principal investigator 1 Boehringer Ingelheim International GmbH $81.62 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722972
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722974
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722976
Principal investigator 1 Boehringer Ingelheim International GmbH $442.20 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722978
Principal investigator 1 Boehringer Ingelheim International GmbH $20.88 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722980
Principal investigator 1 Boehringer Ingelheim International GmbH $41.40 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722982
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,255.00 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800060
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,750.00 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800062
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,135.00 04/16/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800936
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $325.00 04/16/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800938
Principal investigator 1 ModernaTX, Inc. $1,869.00 04/09/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age No dispute reported 06/30/2026 1252971123
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722818
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722820
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722822
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722824
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722942
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722944
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722946
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722948
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722950
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,000.00 03/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800934
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,350.00 03/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800058
Principal investigator 1 Currax Pharmaceuticals LLC $1,846.65 03/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717577
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 03/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722812
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 03/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722814
Principal investigator 1 Boehringer Ingelheim International GmbH $4.14 03/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722816
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,289.00 03/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800056
Principal investigator 1 ModernaTX, Inc. $24,494.80 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971009
Principal investigator 1 ModernaTX, Inc. $1,373.70 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971011
Principal investigator 1 ModernaTX, Inc. $6,949.25 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971029
Principal investigator 1 ModernaTX, Inc. $7,503.10 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971117
Principal investigator 1 ModernaTX, Inc. $7,348.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005805
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,955.40 03/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800932
Principal investigator 1 Currax Pharmaceuticals LLC $45,981.35 03/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717487
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722804
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722806
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722808
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722810
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722920
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722922
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722924
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722926
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 03/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722928
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722930
Principal investigator 1 ModernaTX, Inc. $14,330.75 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971015
Principal investigator 1 ModernaTX, Inc. $8,610.80 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971079
Principal investigator 1 ModernaTX, Inc. $33,753.50 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971103
Principal investigator 1 ModernaTX, Inc. $2,758.80 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971107
Principal investigator 1 ModernaTX, Inc. $19,206.15 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971109
Principal investigator 1 ModernaTX, Inc. $1,437.82 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252971127
Principal investigator 1 ModernaTX, Inc. $1,045.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005801
Principal investigator 1 ModernaTX, Inc. $7,014.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005813
Principal investigator 1 ModernaTX, Inc. $4,030.00 02/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252971089
Principal investigator 1 Boehringer Ingelheim International GmbH $61.07 02/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722932
Principal investigator 1 Boehringer Ingelheim International GmbH $486.42 02/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722934
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 02/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722936
Principal investigator 1 Boehringer Ingelheim International GmbH $4.14 02/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722938
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,446.90 02/20/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800930
Principal investigator 1 ModernaTX, Inc. $40,126.10 02/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971155
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $86.00 02/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220807449
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $86.00 02/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220807459
Principal investigator 1 PFIZER INC. $55,582.50 02/12/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1228719891
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,189.00 02/11/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800928
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 02/11/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220807457
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,384.00 02/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190310576
Principal investigator 1 ModernaTX, Inc. $9,850.89 02/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 No dispute reported 06/30/2026 1252970993
Principal investigator 1 ModernaTX, Inc. $956.21 02/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 No dispute reported 06/30/2026 1252971047
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722796
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722798
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722800
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722802
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722910
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722912
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722914
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722916
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722918
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2025 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518344
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 01/31/2025 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518349
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2025 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518352
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2025 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518356
Principal investigator 1 Currax Pharmaceuticals LLC $2,200.00 01/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717301
Principal investigator 1 Currax Pharmaceuticals LLC $3,939.04 01/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717323
Principal investigator 1 AstraZeneca Pharmaceuticals LP $77,839.00 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185543060
Principal investigator 1 ModernaTX, Inc. $7,189.10 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252971005
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,176.00 01/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800054
Principal investigator 1 Eli Lilly and Company $1,260.43 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187893056
Principal investigator 1 ModernaTX, Inc. $3,720.20 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971025
Principal investigator 1 ModernaTX, Inc. $10,298.95 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971027
Principal investigator 1 ModernaTX, Inc. $1,373.70 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971069
Principal investigator 1 ModernaTX, Inc. $22,929.20 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971119
Principal investigator 1 ModernaTX, Inc. $31,768.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971139
Principal investigator 1 ModernaTX, Inc. $4,514.40 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971149
Principal investigator 1 ModernaTX, Inc. $17,702.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005807
Principal investigator 1 ModernaTX, Inc. $1,520.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005817
Principal investigator 1 ModernaTX, Inc. $12,540.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005823
Principal investigator 1 ModernaTX, Inc. $4,800.00 01/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252971051
Principal investigator 1 ModernaTX, Inc. $400.00 01/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252971053
Principal investigator 1 ModernaTX, Inc. $68.30 01/23/2025 Non-covered Recipient Entity
Velocity Clinical Research - Valparaiso
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252971067
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,408.80 01/22/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220800926
Principal investigator 1 ModernaTX, Inc. $9,296.70 01/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age No dispute reported 06/30/2026 1252970995
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28,101.00 01/17/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220800052
Principal investigator 1 Eli Lilly and Company $27,510.00 01/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187892184
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278193
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278195
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278233
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278235
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278237
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278239
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278241
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278243
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278245
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278247
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278249
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278251
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278253
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278255
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278257
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278259
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278261
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278263
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278265
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278267
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278269
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278271
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278273
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278275
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278277
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278279
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278281
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278283
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278285
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278287
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278289
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278291
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278293
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278951
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278953
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278955
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278957
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278959
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278961
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278963
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278965
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278967
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278969
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278971
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278973
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278975
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278977
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278979
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278981
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278983
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278985
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278987
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278989
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278991
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278993
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278995
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278997
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278999
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185279001
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185279035
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185279037
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185279039
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185279041
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185279043
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185279045
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185279047
Principal investigator 1 Seqirus USA Inc $506.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185279171
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,516.20 01/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185543056
Principal investigator 1 AstraZeneca Pharmaceuticals LP $207,976.80 01/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185543064
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722788
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722790
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722792
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220722794
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722902
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722904
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722906
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722908
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220722940